Eric Raymond
#131,805
Most Influential Person Now
Researcher
Eric Raymond's AcademicInfluence.com Rankings
Eric Raymondcomputer-science Degrees
Computer Science
#5832
World Rank
#6155
Historical Rank
Artificial Intelligence
#1930
World Rank
#1963
Historical Rank
Database
#2955
World Rank
#3082
Historical Rank
Download Badge
Computer Science
Eric Raymond's Degrees
- PhD Computer Science Stanford University
- Bachelors Computer Engineering Carnegie Mellon University
Similar Degrees You Can Earn
Why Is Eric Raymond Influential?
(Suggest an Edit or Addition)Eric Raymond's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) (3188)
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) (2654)
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011) (2225)
- Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. (2006) (1133)
- Current development of mTOR inhibitors as anticancer agents (2006) (945)
- Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. (2002) (835)
- Molecular basis for sunitinib efficacy and future clinical development (2007) (660)
- Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. (2013) (652)
- mTOR-targeted therapy of cancer with rapamycin derivatives. (2005) (607)
- Oxaliplatin: a review of preclinical and clinical studies. (1998) (581)
- Oxaliplatin: mechanism of action and antineoplastic activity. (1998) (521)
- Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. (2004) (506)
- Targeting the TGFβ pathway for cancer therapy. (2015) (500)
- Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. (2008) (496)
- Cellular and molecular pharmacology of oxaliplatin. (2002) (466)
- ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas (2016) (419)
- Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. (1997) (395)
- Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. (1999) (340)
- Oxaliplatin-induced damage of cellular DNA. (2000) (289)
- Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. (2003) (279)
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. (2009) (274)
- New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. (2006) (254)
- [Targeted therapies in hepatocellular carcinoma]. (2010) (242)
- Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers (1997) (239)
- Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. (2008) (230)
- MEK in cancer and cancer therapy. (2014) (224)
- Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. (2008) (224)
- Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. (2000) (217)
- Lessons learned in the development of targeted therapy for malignant gliomas (2007) (204)
- Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy (2012) (194)
- Unraveling galectin-1 as a novel therapeutic target for cancer. (2014) (178)
- Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST) (2007) (172)
- Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. (2007) (170)
- New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. (2012) (168)
- Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. (2001) (167)
- Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma (2018) (162)
- Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines (1999) (154)
- Novel TGF-β inhibitors ready for prime time in onco-immunology (2016) (153)
- Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. (2010) (144)
- Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. (2012) (141)
- In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. (1998) (132)
- Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. (1998) (128)
- Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. (2014) (127)
- Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas (2013) (125)
- Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). (2011) (123)
- Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. (1999) (120)
- Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. (2002) (118)
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma (2012) (117)
- Cancer wars: natural products strike back (2014) (114)
- Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) (2020) (113)
- Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines (2008) (108)
- End points for new agents in induction chemotherapy for locally advanced head and neck cancers. (2002) (106)
- mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? (2008) (106)
- Stromal expression of SPARC in pancreatic adenocarcinoma (2013) (103)
- Targeting cancer cell metabolism in pancreatic adenocarcinoma (2015) (101)
- Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours (2009) (101)
- Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. (2012) (101)
- Impact of the COVID-19 Outbreak on the Management of Patients with Cancer (2020) (99)
- Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. (1999) (99)
- Targeting the Ras–ERK pathway in pancreatic adenocarcinoma (2013) (95)
- Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. (2005) (91)
- Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients (2015) (89)
- Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study. (2004) (88)
- OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. (2014) (88)
- Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck (2001) (86)
- Activity of oxaliplatin against human tumor colony-forming units. (1998) (86)
- Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study (2016) (84)
- Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma (2004) (83)
- Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. (2011) (82)
- Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors (2008) (82)
- Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. (2003) (82)
- Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC) (2007) (82)
- Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib (2011) (82)
- Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. (2016) (79)
- Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas (2015) (79)
- Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision Repair and Is Correlated with XPG Expression in Solid Tumor Cells (2004) (77)
- Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. (2005) (76)
- Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma (2009) (76)
- Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. (2005) (76)
- New developments in multitargeted therapy for patients with solid tumours. (2008) (75)
- Antiproliferatiye effects of recombinant human bone morphogenetic protein‐2 on human tumor colony‐forming units (1998) (73)
- Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma (2019) (73)
- Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. (2003) (73)
- Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. (2002) (73)
- Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. (2014) (73)
- New inhibitors of the mammalian target of rapamycin signaling pathway for cancer (2010) (72)
- Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells (2008) (68)
- Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure (2013) (68)
- Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. (2004) (67)
- Agents that target telomerase and telomeres. (1996) (66)
- Preclinical and clinical development of novel agents that target the protein kinase C family. (2006) (65)
- Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer (2018) (64)
- Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? (2005) (64)
- Mechanisms of action of tasquinimod on the tumour microenvironment (2013) (63)
- Preclinical and clinical strategies for development of telomerase and telomere inhibitors. (1997) (61)
- Tyrosine kinase inhibition and grey hair (2003) (61)
- Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. (1999) (59)
- Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer (2010) (58)
- Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells (2011) (58)
- Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam (2005) (58)
- Detection of circulating carcinoma cells by telomerase activity (2001) (58)
- Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. (2003) (56)
- Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. (2009) (55)
- Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials (2003) (55)
- Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy. (2019) (54)
- Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. (2003) (54)
- Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. (1997) (53)
- Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. (2010) (53)
- Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature (2014) (52)
- Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngealtype (1999) (52)
- Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. (2002) (52)
- Activity of temozolomide against human tumor colony-forming units. (1997) (51)
- Resistance to human epidermal growth factor receptor type 2-targeted therapies. (2014) (50)
- Gemcitabine in elderly patients with advanced pancreatic cancer. (2011) (50)
- Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. (2009) (50)
- Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? (2009) (49)
- Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients (2011) (48)
- Oxaliplatin in colorectal cancer: an overview. (2000) (48)
- Novel molecular therapies in hepatocellular carcinoma (2011) (47)
- Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma (2013) (45)
- Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial (2016) (45)
- Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. (2007) (45)
- Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. (2002) (44)
- Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection (2012) (44)
- Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. (2011) (44)
- A phase 2 study of a novel transforming growth factor-beta (TGF-{beta}1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). (2014) (44)
- Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. (2002) (43)
- Epstein‐Barr virus‐related localized hepatic lymphoproliferative disorders after liver transplantation (1995) (42)
- Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells (2008) (41)
- FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. (2012) (40)
- Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer (2013) (40)
- First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. (2010) (40)
- Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib (2012) (40)
- Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors (2011) (39)
- Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. (2008) (39)
- OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations (2016) (39)
- A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. (2001) (38)
- Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. (2012) (38)
- Understanding c-MET signalling in squamous cell carcinoma of the head & neck. (2017) (38)
- Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. (2011) (37)
- Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). (2010) (37)
- Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. (2003) (37)
- Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib (2013) (37)
- Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours (2018) (37)
- Could we expect to improve survival in small cell lung cancer? (2007) (36)
- Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. (2004) (36)
- Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients (2014) (36)
- [Oxaliplatin: the first DACH platinum in clinical practice]. (1997) (36)
- Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors (2011) (36)
- Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. (2009) (36)
- Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. (1997) (36)
- Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms (2018) (35)
- Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib (2013) (35)
- Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells (2006) (35)
- Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. (2012) (35)
- Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib (2020) (34)
- Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. (2010) (34)
- Single agent and combination studies of pralatrexate and molecular correlates of sensitivity (2010) (33)
- Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound (2013) (33)
- Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer Cells (2010) (33)
- A Risk-Benefit Assessment of Amifostine in Cytoprotection (1999) (33)
- Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. (2014) (32)
- Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential (2012) (32)
- Antiangiogenic treatments and mechanisms of action in renal cell carcinoma (2012) (32)
- Early development of sunitinib in hepatocellular carcinoma (2009) (31)
- Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients (2004) (30)
- DNA G-Quadruplexes, Telomere-Specific Proteins and Telomere-Associated Enzymes as Potential Targets for New Anticancer Drugs (2000) (30)
- Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies (2012) (29)
- [PI3K-AKT-mTOR pathway and cancer]. (2012) (28)
- Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas. (2001) (28)
- Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. (1999) (28)
- Bimonthly high dose leucovorin and 5‐fluorouracil 48‐hour continuous infusion in patients with advanced colorectal carcinoma (1997) (28)
- Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. (2002) (28)
- Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). (2011) (28)
- Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data. (2017) (28)
- Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: A phase II study (2007) (27)
- Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells (2007) (27)
- Temozolomide: A Safe and Effective Treatment for Malignant Digestive Endocrine Tumors (2009) (27)
- Benzofuran derivatives as anticancer inhibitors of mTOR signaling. (2014) (27)
- Sunitinib in pancreatic neuroendocrine tumors (2012) (27)
- [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD]. (1997) (26)
- Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib (2011) (26)
- Benzofuran derivatives as a novel class of inhibitors of mTOR signaling. (2014) (26)
- 716 Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 H infusion in pretreated metastatic colorectal cancer (CRC) (1995) (26)
- Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer (2009) (25)
- A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). (2016) (24)
- Sunitinib paves the way for targeted therapies in neuroendocrine tumors (2009) (24)
- High c‐Met expression in stage I–II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis (2015) (24)
- Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib (2016) (23)
- Reports of Clinical Benefit of Plitidepsin (Aplidine), a New Marine-Derived Anticancer Agent, in Patients With Advanced Medullary Thyroid Carcinoma (2009) (23)
- A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay (1999) (23)
- Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice (2000) (22)
- Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response (2017) (22)
- Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status. (2002) (22)
- Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies. (2011) (21)
- A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. (2014) (21)
- Dimethyl sulfoxide (DMSO) causes a reversible inhibition of telomerase activity in a Burkitt lymphoma cell line. (1998) (20)
- A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. (2000) (20)
- First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. (2011) (20)
- Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. (2000) (19)
- Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study (2005) (19)
- Efficacy of the metastatic survey in the staging of gestational trophoblastic disease (1990) (19)
- Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. (1995) (19)
- GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma (2019) (18)
- A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors (2007) (18)
- Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression (2021) (18)
- Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib (2021) (18)
- Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). (2012) (18)
- Bimonthly high dose leucovorin and 5‐fluorouracil 48‐hour infusion with interferon‐alpha‐2a in patients with advanced colorectal carcinoma (1997) (17)
- Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study. (2016) (17)
- A phase I study of AVE1642, a human monoclonal antibody-blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC). (2011) (17)
- Soft tissue sarcomas. Case 3. Gastrointestinal stromal tumor and Carney's triad. (2004) (17)
- Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. (2019) (17)
- The role of integrins in colorectal cancer. (2007) (17)
- A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors (2014) (16)
- Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials (2004) (16)
- Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study (2016) (16)
- Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma (2014) (16)
- Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies (1998) (16)
- Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability. (2014) (16)
- Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features (2015) (16)
- GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions (2020) (16)
- CAPRA: Safety, efficacy, and translational biomarkers of weekly everolimus, carboplatin, and paclitaxel as induction therapy for locally advanced head and neck squamous cell carcinoma (HNSCC). (2013) (15)
- Phase III, Randomized, Double-blind Trial of Sunitinib Versus Placebo in Patients With Progressive, Well-differentiated Pancreatic Islet Cell Tumours (2009) (15)
- Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers (2016) (15)
- Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects (2019) (15)
- Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis (2013) (15)
- Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters (2008) (15)
- Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. (2013) (15)
- Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma. (1997) (14)
- Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development (2010) (14)
- Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors (2015) (14)
- Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): Safety, efficacy, and updated translational results. (2015) (14)
- Synergy between the non‐classical thymidylate synthase inhibitor AG337 (ThymitaqR) and cisplatin in human colon and ovarian cancer cells (1996) (14)
- Logistic regression model of fotemustine toxicity combining independent phase II studies (1996) (13)
- Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E (2000) (13)
- LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (2022) (13)
- Phase I population pharmacokinetics of irofulven (2003) (13)
- A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors (2006) (13)
- The immunosuppressive effect of vincristine on allostimulatory potential of human dendritic cells interferes with their function and survival. (2004) (13)
- Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. (2010) (13)
- Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial. (2013) (12)
- Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors. (2015) (12)
- PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma (2020) (12)
- Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET). (2010) (12)
- Mechanism of action of rapalogues: the antiangiogenic hypothesis. (2008) (12)
- Consensus Guidelines for High Grade Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumours and Neuroendocrine Carcinomas (NEC). (2016) (12)
- 604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial (2012) (12)
- Systemic therapeutic strategies for GEP-NETS: what can we expect in the future? (2014) (12)
- Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck. (2004) (12)
- Reinvention of chemotherapy: drug conjugates and nanoparticles (2015) (11)
- Protein kinase C α and δ are members of a large kinase family of high potential for novel anticancer targeted therapy (2006) (11)
- Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma. (1997) (11)
- Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome (2015) (11)
- Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover. (2016) (11)
- Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors (2015) (11)
- Metabolism of Irinotecan ( CPT-11 ) by CYP 3 A 4 and CYP 3 A 5 in Humans 1 (2000) (10)
- Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10min infusion every 3 weeks in patients with advanced solid tumours (2002) (10)
- Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors. (1999) (10)
- New treatment options with cytotoxic agents in neuroendocrine tumours (2012) (10)
- Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib? (2016) (10)
- ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours (2021) (10)
- PDGFR inhibition in brain tumours--oft expectation fails where most it promises. (2009) (9)
- Abstract A72: A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors. (2013) (9)
- [Tumor angiogenesis inhibitors: media and scientific aspects]. (1998) (9)
- Phase I–II and pharmacokinetic study combining gemcitabine (GEM) with oxaliplatin (OX) in patients (pts) with advanced non-small-cell lung (NSCLC) and ovarian carcinoma (OC) (2001) (9)
- [Zd 1839 "Iressa"]. (2000) (9)
- 616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma (2012) (9)
- [Targeted therapies in hepatocellular carcinomas: recent results and future development]. (2009) (9)
- Efficacy of venlafaxine for the prevention and relief of acute neurotoxicity of oxaliplatin: Results of EFFOX, a randomized, double-blinded, placebo-controlled prospective study. (2009) (9)
- Abstract 2094: Effects of TGF-beta signaling inhibition with LY2157299 in hepatocarcinoma models and in ex vivo whole tumor tissue samples from patient specimen. (2013) (8)
- Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors. (2011) (8)
- Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide). (2002) (8)
- Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms. (2005) (8)
- [Preclinical studies of oxaliplatin in combination chemotherapy]. (2001) (8)
- Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies (2014) (8)
- Future perspectives on neuroendocrine tumors (2011) (8)
- Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours. (2014) (8)
- Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies. (2008) (8)
- Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus (2012) (7)
- Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models (2019) (7)
- Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial (2020) (7)
- [Rapamycin and CCI-779]. (1999) (7)
- The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors. (2017) (7)
- BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC. (2016) (7)
- Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. (2011) (7)
- Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo. (2011) (7)
- Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies (2006) (7)
- Abstract 33: OTX008 pharmacokinetics (PK) during the first-in-man phase I study in patients with advanced solid tumors . (2013) (6)
- Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial. (2013) (6)
- Induction chemotherapy challenges for head and neck cancer. (2013) (6)
- Phase I (PI) trials with aplidine (APL), a new marine derived anticancer compound (2001) (6)
- 704 POSTER A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients (HRPC) (2007) (6)
- 6501 Sunitinib (SU) vs placebo for treatment of progressive, well- differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial (2009) (6)
- Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC). (2013) (6)
- [Adamantinoma of the proximal end of the tibia. A case]. (1994) (6)
- Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients. (2009) (6)
- O126 EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-β RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD (2014) (6)
- Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck (2005) (6)
- [Advanced hepatocellular carcinoma: importance of clinical trials]. (2015) (6)
- 600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors (2012) (6)
- [Irinotecan: various administration schedules, study of drug combinations, phase I experience]. (1998) (6)
- Les carcinomes du nasopharynx (2000) (5)
- Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. (2019) (5)
- Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). (2011) (5)
- Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) (2012) (5)
- Telomerase and telomere inhibitors in preclinical development. (1997) (5)
- First-in-human phase I and pharmacokinetic study of DTS-108 in patients with advanced carcinomas. (2012) (5)
- [Topics in mTOR pathway and its inhibitors]. (2009) (5)
- 3535 POSTER Phase II trial investigating the efficacy and safety of sunitinib in patients with unresectable hepatocellular carcinoma (HCC) (2007) (5)
- Bioisosteric modification of flavaglines (2016) (5)
- Oxaliplatin: Update on a Active and Safe Dach Platinum Complex (1996) (5)
- Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. (2015) (5)
- Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer. (1996) (5)
- 552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study (2003) (5)
- FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients. (2011) (5)
- Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position. (2018) (4)
- Methylguanine DNA methyl transferase (MGMT) expression predicts response to temozolomide (TMZ) in patients with digestive neuroendocrine tumors (NETs) (2012) (4)
- 846P PHASE III TRIAL OF SUNITINIB (SU) VERSUS PLACEBO (PBO) FOR TREATMENT OF PANCREATIC NEUROENDOCRINE TUMORS (NET): IMPACT OF SOMATOSTATIN ANALOGUE (SSA) TREATMENT ON PROGRESSION-FREE SURVIVAL (PFS) (2010) (4)
- Translational Rational for the Clinical Development of OTX-008: A Novel Drug That Inhibits Galectin-1 Expression in Human Cancer Models (2012) (4)
- Mechanism of action of rapalogues: the antiangiogenic hypothesis (2008) (4)
- PHASE III STUDY OF SUNITINIB VS PLACEBO IN PATIENTS (PTS) WITH ADVANCED, UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMOR (NET) (2012) (4)
- Blinded independent central response assessment using RECIST, mRECIST, and CHOI criteria in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC). (2012) (4)
- Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors (2020) (4)
- Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts). (2011) (4)
- Cellular and molecular mechanisms of action of AS703569, a novel aurora kinase inhibitor, in human cancer cell lines (2007) (4)
- A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors. (2006) (4)
- Population pharmacokinetics and pharmacokinetic‐pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies (2002) (4)
- Bioactive Flavaglines: Synthesis and Pharmacology (2015) (4)
- Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract (2014) (4)
- 720PSECOND LINE THERAPY WITH SUNITINIB AS SINGLE AGENT IN PATIENTS WITH ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA (UPDATE ON SUN-CK PHASE II TRIAL). (2014) (4)
- AS703569, a novel aurora kinase inhibitor, enhances the antiproliferative effects of other targeted therapies in human cancer cell lines (2007) (4)
- Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors. (2012) (4)
- Neuroendocrine tumors and CUP (2012) (4)
- Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies. (2004) (4)
- Contemporary reviews on cancer treatment (2015) (4)
- Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study (2022) (3)
- First-in-human phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of oral GNS561, a palmitoyl-protein thioesterase 1 (PPT1) inhibitor, in patients with primary and secondary liver malignancies. (2021) (3)
- c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside. (2016) (3)
- [Prognosis factors of cholangiocarcinoma: contribution of recent molecular biology tools]. (2009) (3)
- Abstract 3000: Angiogenic recovery under chronic exposure to sunitinib is associated with vasculogenic mimicry in renal cell carcinoma (2014) (3)
- A bulky single mass of the liver that revealed a primary hepatic leiomyosarcoma (2006) (3)
- Final phase Ib data for the oral c-Met inhibitor tepotinib in patients with previously treated advanced hepatocellular carcinoma. (2017) (3)
- PD-020Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib (2016) (3)
- 6569 POSTER Updated Overall Survival Data From a Phase III Study of Sunltlnlb Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET) (2011) (3)
- 565 Preclinical evaluation of OTX015, a novel BET-BRD inhibitor, on small cell lung cancer (SCLC) cell lines (2014) (3)
- Preclinical Rational, Safety, and Preliminary Efficacy Results of Weekly Everolimus, Carboplatin and Paclitaxel as An Induction Therapy for Patients with Unresectable Locally Advanced Head & Neck Squamous Cell Carcinoma (CAPRA): A GERCOR-IRC Phase I/II Study (2012) (3)
- Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies (2004) (3)
- Abstract B175: TGF-β-RI kinase inhibitors LY2157299 and LY364947 decrease motility and invasion in hepatocarcinoma (HCC) cells developing resistance to VEGFR/PDGFR kinase inhibitors. (2011) (3)
- TOR (target of rapamycin) as an anti-cancer target (2007) (3)
- Regorafenib for metastatic colorectal cancer (2013) (3)
- [Epidermal growth factor inhibitors]. (2003) (2)
- Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN). (2016) (2)
- Oxaliplatin, leucovorin and fluorouracil in pretreated patients with advanced colorectal cancer. (1997) (2)
- 568 Design of PTX008 That Allosterically Targets Galectin-1 to Inhibit Tumor Growth in Mice (2012) (2)
- Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules (2005) (2)
- Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients. (1996) (2)
- Rationale for targeted therapies in hepatocellular carcinoma (2008) (2)
- Updated Overall Survival Data From a Phase III Study of Sunitinib Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET) (2011) (2)
- Abstract 4488: Everolimus (RAD001) activity in renal and hepatocellular carcinoma cells resistant to sunitinib and sorafenib (2011) (2)
- A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC). (2019) (2)
- [Carcinoma of the nasopharynx]. (2000) (2)
- Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates (2019) (2)
- 143 POSTER Ex-vivo plasma protein binding and in vitro evaluation of AP5346 (ProLindac TM; PL), a novel polymer-bound platinum: Evidence showing that >72 h DACH-platinum (Pt) release may play a major role in cytotoxicity (2008) (2)
- [Chemotherapy of colorectal cancers with metastases]. (1996) (2)
- [Targeted therapies and their indications in solid neoplasias]. (2009) (2)
- [Leser-Trelat sign and hypercorticism associated with metastatic adenocarcinoma of unknown origin]. (1994) (2)
- Abstract C261: Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) in hepatocellular carcinoma (HCC) compared to glioma patients. (2013) (2)
- Abstract 2754: Phase I and pharmacokinetic (PK) study of two regimens combining the aurora kinase inhibitor AS703569 and gemcitabine in patients with advanced solid tumors (2010) (2)
- First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers (2022) (2)
- 7030 Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts) (2009) (2)
- Abstract 3289: PTX-008, a dual inhibitor of angiogenesis and tumor cell proliferation, potentiates the antineoplastic activity of targeted therapies in human tumor models (2011) (2)
- Phase I study of elisidepsin (E) in combination with carboplatin (C) in patients (pts) with advanced solid tumors. (2011) (2)
- Bevacizumab administered intraperitoneally as palliative treatment of malignant refractory ascites. (2014) (2)
- C-MET expression as an independent prognostic marker in resected pancreatic ductal adenocarcinoma (PDAC): Proposition of a novel reliable immunostaining scoring method. (2014) (2)
- P-118Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial (2015) (2)
- 374 Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) results of first-in-man phase I trial of the orally available MEK-inhibitor MSC1936369 (AS703026) in patients (pts) with advanced solid tumors (2010) (2)
- Are natural products still of interest compared with molecular-targeted therapy for the treatment of cancer? (2004) (2)
- Clinical activity of irofulven in hormone refractory prostate cancer. (2004) (2)
- [Phase I cancer trials methodology]. (2007) (2)
- 567 OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines (2014) (2)
- In vitro Anti-proliferative Effects of ProLindac™, a Novel Dach-Platinum-Linked Polymer Compound, as a Single Agent and in Combination with Other Anti-cancer Drugs (2009) (2)
- SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates. (2020) (2)
- [Cancer of the kidney: changes in blood lymphocyte subsets induced by treatment with interferon alpha-2b and interleukin-2r]. (1993) (2)
- Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC). (2011) (2)
- 217 Specific TGF-beta receptor-I inhibition using LY364947 impairs signaling, motility, and invasion in parental and multikinase inhibitor-resistant hepatocarcinoma cells (2010) (2)
- Abstract B166: Effects of PTX‐008, a non‐peptidic topomimetic targeting galectin‐1 in human epithelial cancer cells (2009) (1)
- Gastrontestinal stromal tumor and carney's triad (2004) (1)
- Value of preoperative biopsy and radiological assessment for the diagnosis of mixed hepatocellular cholangiocarcinoma (HCC-CC). (2012) (1)
- Abstract 1926: Antitumor and antiangiogenic effects of OTX-008, a novel calyx[4]arene, are mediated by galectin-1 inhibition in human tumor xenograft models (2012) (1)
- Baseline pathological and radiological assessment of tumor angiogenesis predicts survival in patients with oligodendrogliomas. (2004) (1)
- Phase I study of MGI 114 (Irofulven) given as either D1, D8 q3 weeks or D1, D5 q4 weeks schedule (sch) as a 30 minute infusion in advanced solid tumors (AST): preliminary results (2001) (1)
- Management of neuromuscular dose limiting toxicity at the early stage of drug development. (2006) (1)
- Evaluation of antiangiogenic effects: biomarkers and functional imaging (2010) (1)
- [Interferon and interleukin 2 in metastatic cancer of the kidney. Apropos of 18 cases]. (1991) (1)
- Omics and Prognostic Markers (2010) (1)
- Beyond outstanding results with VEGFR/PDGFR inhibitors in advanced hepatocellular carcinoma: can imaging help where biomarkers keep us waiting? (2007) (1)
- Abstract 1805: Comparative analysis of 3 rapalogues, everolimus, temsirolimus and sirolimus, in hepatocarcinoma and renal cancer models resistant to VEGFR inhibitors (2012) (1)
- 745TiPPHASE IB/II, MULTICENTER, SINGLE-ARM TRIAL OF THE ORAL C-MET INHIBITOR MSC2156119J AS MONOTHERAPY IN PATIENTS WITH MET-POSITIVE ADVANCED HEPATOCELLULAR CARCINOMA WITH CHILD-PUGH CLASS A LIVER FUNCTION WHO FAILED SORAFENIB TREATMENT. (2014) (1)
- 359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors (2004) (1)
- [Chemoprotectors. Mechanisms of action and clinical applications]. (1996) (1)
- Abstract 2752: Effects of Debio 1143, a novel oral IAP inhibitor, in monotherapy and in combination with platinum drugs in human SCCHN tumor specimens (2014) (1)
- FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients. (2011) (1)
- POD-11.01: Dose Finding and Safety Analysis of Inecalcitol in Combination with Docetaxel-Prednisone Regimen in Hormone-Refractory Prostate Cancer (HRPC) Patients (PTS) (2009) (1)
- Phase I study of MGI 114 (irofulven) exploring 3 different iv schedules (SCH) as a 5 minute infusion in advanced solid tumors (AST): final results (2001) (1)
- Abstract 4520: Targeting galectin-1 with PTX-008 inhibits invasion, tumor growth and metastasis in human carcinoma models (2011) (1)
- [Chemotherapy with cisplatinum, carboplatin and 5FU-folinic acid, followed by concomitant chemo-radiotherapy in unresectable esophageal carcinomas]. (2001) (1)
- Abstract 2944: TGF-β inhibitor galunisertib combined with antiangiogenic therapies showed antitumor effects in vitro and in vivo in hepatocellular carcinoma (HCC) (2018) (1)
- 557 Hydroxyurea, folinic acid, 5FU bolus and infusion (HLFP regimen) in advanced gastric cancer (1995) (1)
- Abstract B141: Effects of AZD8055, a novel mTOR kinase inhibitor, in human cancer cells developing resistance to rapamycin (2009) (1)
- 693PNAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) VS GEM ALONE FOR PATIENTS (PTS) WITH METASTATIC PANCREATIC CANCER (PC): SUBGROUP ANALYSES OF THE MPACT TRIAL BASED ON THE PRESENCE OF LIVER METASTASES (LMS) AND NUMBER OF METASTATIC SITES. (2014) (1)
- New treatments of pancreatic neuroendocrine tumors: why using them? How to use them? (2012) (1)
- mTOR and Cancer Therapy: Clinical Development and Novel Prospects (2009) (1)
- 398 Benchmarking the Allosteric MEK Inhibitors UO126, AZD6244, AS703026, and GSK1120212 Shows Differences in Potency to Inhibit ERK Phosphorylation, Proliferation, and Invasion in Pancreatic Cancer Models (2012) (1)
- Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation (2014) (1)
- [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs]. (1997) (1)
- 58 POSTER Antiangiogenic and anti-invasive activities of the kinase inhibitor sunitinib malate on experimental human gliobalstoma in vitro and in vivo (2006) (1)
- Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression (2021) (1)
- 564 OTX015, a novel BET-BRD inhibitor is active in non-small-cell lung cancer cell (NSCLC) lines harboring different oncogenic mutations (2014) (1)
- [Gemcitabine and pemetrexed: novel associations and mechanisms of resistance]. (2007) (1)
- [Metastatic eye neoplasms. Review of the literature apropos of 4 cases]. (1994) (1)
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. (2023) (1)
- Abstract 1673: Galunisertib combined with sorafenib affects proliferation, EMT and delays tumor growth in mice and in hepatocellular carcinoma (HCC) patient samples ex vivo (2015) (1)
- E. Chu, V.T. DeVita Jr (eds). Physicians’ Cancer Chemotherapy Drug Manual 2001 (2002) (1)
- Predictive Biomarkers of Response to mTOR Inhibitors (2016) (1)
- Irofulven (IROF) combined with oxaliplatin (OXA) in advanced hepatocellular carcinoma (HCC) patients (pts): Phase I study (preliminary results). (2006) (1)
- Abstract 5530: OTX015, a novel pan BET-BRD inhibitor is active in non-small-cell lung cancer (NSCLC) cell lines bearing the fusion protein EML4-ALK (2014) (1)
- Abstract 4264: CXCL12-CXCR4 axis in sunitinib-sensitive and -resistant hepatocarcinoma cells (2011) (1)
- Phase I and pharmacokinetic study of BBR 2778 (1999) (1)
- Overall Survival (OS) Analysis of Sunitinib (SU) after Adjustment for Crossover (CO) in Patients with Pancreatic Neuroendocrine Tumors (NET) (2011) (1)
- Abstract 1894: Antitumor effects of everolimus, sorafenib, and axitinib in human renal cells carcinoma xenografts resistant to first line treatment by sunitinib (2012) (1)
- Biomarker Development in Targeting Cancer Epigenetic (2016) (1)
- Transcriptomics in Tumor and Normal Tissues and Precision Oncology Algorithms Identify Early-Stage NSCLC Patients with High Risk of Post-Surgery Recurrence Who May Benefit from Adjuvant Therapies (2021) (0)
- Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma. (2020) (0)
- Abstract A238: c-MET as a target for MET inhibitors in patients with poor prognostic pancreatic adenocarcinoma following completed surgical resection. (2013) (0)
- Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus. (2012) (0)
- Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup. (2023) (0)
- Abstract 1542: Molecular mechanisms associated with sensitivity/resistance to PM02734 (Irvalec®), a novel marine-derived cyclic depsipeptide (2010) (0)
- Role of the endothelins and endothelin receptors in cancer cell signaling and angiogenesis (2007) (0)
- Abstract 2043: PlGF/VEGFR-1-dependent activation of Dll4/Notch4 pathway contributes to liver vessel abnormalities and tumor growth in hepatocellular carcinoma (2018) (0)
- Abstract A194: OTX008, a small molecule that inhibits galectin-1, potentiates the in vitro effects of cytotoxic and targeted agents in several human cancer models. (2013) (0)
- Molecular and cellular effects of AP5346, a novel DACH-platinum linked polymer-compound, compared to oxaliplatin and cisplatin in a panel of human cancer cell lines (2007) (0)
- 612 POSTER Acquired resistance to drugs that yield PKCδ activation and PKCα inhibition modify adhesion and invasion in human cancer cells (2006) (0)
- W1133 Are Recist Criteria Accurate to Evaluate Tumor Response to Targeted Therapies in Patients With Digestive Endocrine Tumors (Dets) (2010) (0)
- A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology (2023) (0)
- Abstract 728: CXCL12 (SDF-1) chemokine expression as a baseline factor associated with resistance to induction chemotherapy in head and neck squamous cell carcinoma (2012) (0)
- 418 Phase I, clinical, pharmacokinetic and schedule dependency study of the aurora kinase inhibitor AS703569 combined with gemcitabine in patients with solid tumors (2010) (0)
- Discovery of Sunitinib as a Multitarget Treatment of Cancer (2012) (0)
- Abstract 859: Basal Notch4 activation is a druggable marker of aggressiveness in a panel of human cancer cell lines (2019) (0)
- Abstract A68: Tumor cell dedifferentiation into endothelial cells and resistance to sunitinib in renal carcinoma models (2012) (0)
- Safety, Translational And Preliminary Efficacy Results Of Sunitinib In Patients With Advanced Intrahepatic Cholangiocarcinoma (Sun-Ck): A Gercor-Irc Multicenter Phase II Study (2014) (0)
- 551 Irofulven (IROF) enhances the antiproliferative effects of oxaliplatin (oxa) in human colon and breast cancer cells (2004) (0)
- Abstract 4411: Effects of novel PI3K/mTOR inhibitors BKM120 and BEZ235 in comparison to everolimus in Head & Neck Squamous cell carcinomas (HNSCC). (2013) (0)
- Abstract 5529: In vitro evaluation of OTX015, a novel pan-BET-bromodomain (BET-BRD) inhibitor, as single agent and in combination with standard chemotherapy drugs in human leukemic cell lines (2014) (0)
- Abstract 3261: Cellular effects of MEK inhibition in pancreatic cancer cell lines are not correlated with « classical » predictive markers of response to MEK inhibitors. (2013) (0)
- 146 Specific MET inhibition using SU11274 impairs cholangiocarcinoma cells proliferation, motility and invasion (2010) (0)
- Abstract 685: PTX-008 antiproliferative effects in cancer cells are mediated though galectin-1 inhibition and MAPK-dependent G2/M cell cycle arrest (2011) (0)
- Abstract 3082: Biomarker-driven inhibition of MET and EGFR pathways in hepatocellular and cholangiocarcinoma models (2016) (0)
- Is there still a place for chemotherapy in patients with locally advanced head & neck squamous cell carcinoma? (1999) (0)
- Abstract 5312: Imeglimin alone or in combination with sorafenib showed potent anti-tumor effect in human hepatocellular carcinoma: A new kid on the block for HCC treatment (2020) (0)
- Decreased pS6 expression under MEK inhibitor (MEKi) correlates with response to MEKi alone or combined with PI3Ki-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models (2015) (0)
- MEK inhibition blocks S-phase entry in K-Ras mutated pancreatic cancer cell lines (2012) (0)
- Antiproliferative effects of sunitinib and sorafenib, two potent multitarget tyrosine kinase inhibitors, in a panel of human cancer cell lines. (2007) (0)
- Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib (2021) (0)
- 303 POSTER Additive and synergistic effects of irofulven and capecitabine in human prostate cancer cells (2006) (0)
- Strategies targeting the P13k/AKT pathway: rapamycin and its derivatives as lead compounds for downstream inhibition of the P13kinase pathway (2004) (0)
- Abstract B4: Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts (2012) (0)
- Author response for "ENETS consensus guidance for synoptic reporting of molecular imaging studies" (2021) (0)
- Abstract 91: Diet-variants and immune characterization of a stage-defined, transgenic immunocompetent mouse model of HCC (ASV-B) (2019) (0)
- Pharmacokinetics (PK) of irofulven using two different intermittent dosing schedules as a 30 minute (MIN) infusion in advanced solid tumors (AST): Preliminary data (2001) (0)
- Prognostic value of high c-Met expression in patients with poor prognosis pancreatic adenocarcinoma (PAC) following surgical resection: comparison of three c-Met scoring methods and exploration of underlying mechanisms of c-Met overexpression (2015) (0)
- Abstract 321: S49076, a novel kinase inhibitor of MET, AXL and FGFR, demonstrates marked in vitro and in vivo efficacy in hepatocellular carcinoma (2016) (0)
- Electrophoresis of Lactate Dehydrogenase Isoenzymes ITXd 1 (2004) (0)
- Abstract B145: Addition of galunisertib to DC101 improved angiogenesis inhibition and tumor growth control in hepatocellular carcinoma (HCC) (2018) (0)
- Abstract 1548: PTX-008, a designed mimetic of anginex, potentiates the effects of the VEGFR/PDGFR inhibitor sunitinib (2010) (0)
- Phase I dose finding study with irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfynction (1999) (0)
- Abstract 3824: c-MET as a prognostic biomarker and therapeutic target in patients with poor prognostic pancreatic adenocarcinoma following surgical resection (2014) (0)
- Abstract C268: MET-inhibition using SU11274 and HER-inhibitions with lapatinib impair proliferation, motility and invasion in hepatocellular carcinoma (HCC) and exhibits an increased efficacy un sorafenib-tolerant model. (2013) (0)
- Antiproliferative activity of AS703569, a novel aurora kinase inhibitor, given as a single agent and in combination with EGFR inhibitors in human head and neck squamous cell carcinoma (HNSCC). (2007) (0)
- Abstract 321: Sunitinib alternated with everolimus in renal cell carcinoma: a sequential combination strategy for antitumor efficacy in mice clinical trial. (2013) (0)
- Abstract 4466: New biomarkers to optimize preclinical development of the PDI inhibitor XCE853 (2015) (0)
- [Epidermoid carcinoma of the head and neck: contribution of chemotherapy in case of recurrence and locally advanced disease. Review of the literature]. (2000) (0)
- Activity of oxaliplatin and 5-fluorouracil/folinic acid (FOLFOX2) in elderly patients with simultaneous advanced colon (ACC) and Hormone refractory prostate cancer (HRPC) (2004) (0)
- Abstract B144: LY3039478, a novel Notch inhibitor, potentiates the antitumor effects of sorafenib in hepatocellular carcinoma (HCC) (2018) (0)
- Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects (2019) (0)
- Influence of underlying liver disease on response to sorafenib in patients with advanced hepatocellular carcinoma (HCC). (2011) (0)
- 430 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts) (2010) (0)
- 553 Hydroxyurea, folinic acid, 5FU bolus and infusion (HLFP regimen) in advanced esophageal cancer (1995) (0)
- 104 POSTER Role of P21 in sensitivity to DACH-platinum compounds, oxaliplatin and ProLindac, in human cancer cells (2008) (0)
- [Acute alveolo-interstitial pneumopathies in HIV-negative patients treated with antineoplastic chemotherapy]. (2002) (0)
- Abstract 1732: Biomarker-driven inhibition of MET and EGFR pathways in hepatocellular and cholangiocarcinoma models with increased efficacy in a sorafenib-tolerant model (2014) (0)
- Results of the phase I-II study of gemcitabine (GEM) in combination with oxaliplatin (OX) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) (2000) (0)
- Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumors (2023) (0)
- Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies (2014) (0)
- Liver carcinogenesis related to the metabolic syndrome: Metformin as a new therapeutic tool (2014) (0)
- Abstract 1914: GNS561 is a new quinoline derivative with high efficacy on cancer stem cells from colorectal liver metastasis and hepatocellular carcinoma (2017) (0)
- 494 POSTER Cellular and molecular patterns associated with sensitivity and resistance to enzastaurin in human cancer cells (2008) (0)
- Do combination of chemotherapy (CT) and radiotherapy (RT) modify the patterns of relapse and the late central nervous system toxicity (LCNST) in immunocompetent patients with primary cerebral non-hodgkin's lymphoma? (1999) (0)
- Abstract 3260: Antiproliferative effects of PI3K-mTOR pathway inhibitors alone or in combination with MEK inhibitor GSK1120212 in pancreatic cancer cell lines are not correlated with molecular effects on ERK and S6 phosphorylation. (2013) (0)
- 317 POSTER Antiproliferative effects of PM02734, a novel marine cyclic peptide compared with currently used Erb-B inhibitors, in a panel of human cancer cell lines characterised for Erb-B expression (2008) (0)
- Performance of 18FDG-PET in the management of non-metastatic HIV+ anal squamous cell carcinoma (ASCC). (2017) (0)
- 60 Pathological and radiological assessment of tumor angiogenesis as prognostic factors of survival in patients with oligodendrogliomas (2005) (0)
- Phase I study of PKC412, a protein kinase C inhibitor, in combination with gemcitabine and cisplatin: Preliminary report of an ongoing phase I study (2000) (0)
- Abstract B67: Increased CXCR4 expression and its nuclear localization are associated with invasion in sorafenib and sunitinib-tolerant hepatocarcinoma models (2012) (0)
- Abstract B57: Effects of MEK inhibition alone or in combination with PI3K-mTOR pathway inhibitors in pancreatic ductal adenocarcinoma in vitro and on an innovative ex vivo fresh tumor tissue culture model (2016) (0)
- Effects of the sequential administration of GEMOX followed by FOLFIRI in cholangiocarcinoma. (2014) (0)
- Angiogenesis Inhibition Using Sunitinib in Pancreatic Neuroendocrine Tumors (2014) (0)
- Stromal expression of SPARC in pancreatic adenocarcinoma (2013) (0)
- Abstract B151: Epithelial‐to‐mesenchymal transition (EMT) in resistance to the antiproliferative effects of elisidepsin (Irvalec™), a novel marine‐derived depsipeptide, in colon cancer cells (2009) (0)
- Abstract C161: Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors. (2013) (0)
- 373 INVITED Novel Imaging Techniques and Treatment Assessment for Evaluating Benefit From Targeted Agents (2011) (0)
- Abstract 366: Changes in gene expression profiles in human breast & liver cancer cells and xenografts acquiring resistance to sunitinib (2010) (0)
- Abstract C76: Inhibition of galectin-1 expression by OTX008, a novel calyx[4]arene, is associated with antiproliferative and antiangiogenic activity in human tumor xenograft models. (2011) (0)
- Resistance to PKCδ activators yield an increased endothelin-1-mediated invasive phenotype in human cancer cells (2007) (0)
- Abstract A121: Preclinical evaluation of OTX015 a novel BET-BRD inhibitor across a panel of solid tumor cell lines of different lineages. (2013) (0)
- Specificities and challenges of imaging response in pancreatic neuroendocrine tumors treated with targeted therapies (2012) (0)
- Abstract 4266: Acquired resistance to sorafenib yields CXCL12 (SDF1α) over-expression and increases invasion in hepatocarcinoma cells (2011) (0)
- Abstract B31: Biomarker selection defines a subgroup of hepatocellular carcinoma (HCC) patients with poor prognosis who are candidates for MET inhibition strategy. (2013) (0)
- Abstract 29: Addition of Galunisertib to DC101 increased angiogenesis inhibition and tumor growth control in hepatocellular carcinoma (HCC) (2017) (0)
- Abstract 1636: Diet-variants and immune characterization of a stage-defined, transgenic immunocompetent mouse model of HCC (ASV-B) (2020) (0)
- c-MET as a prognostic biomarker and therapeutic target in patients with poor prognostic pancreatic adenocarcinoma following surgical resection (2014) (0)
- Targeting the Ras–ERK pathway in pancreatic adenocarcinoma (2012) (0)
- Activity of oxaliplatin and 5-fluorouracil/folinic acid (FOLFOX2) in elderly patients with simultaneous advanced colon (ACC) and Hormone refractory prostate cancer (HRPC). (2004) (0)
- 2352 Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma: Final results of the SUN-CK phase II trial from GERCOR IRC (2015) (0)
- A single-institution survey of de novo secondary malignancies in patients occurring after orthotropic liver transplantation. (2012) (0)
- Abstract 2501: Involvement of Notch signaling pathway in a panel of human cancer cell lines (2018) (0)
- Inhibition of mTOR in Neuroendocrine Neoplasms of the Digestive Tract (2014) (0)
- CANCER TREATMENT with aplidine IN COMBINATION WITH CARNITINE OR acetylcarnitine (2001) (0)
- Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients (2019) (0)
- 629 Acquired irofulven-resistance is mediated by a novel and drug-specific resistance mechanism associated with overexpression of ABCA12 (2004) (0)
- Anal cancer prevention: coming soon on the screens? (2017) (0)
- Abstract 2677: Decrease in phospho-S6 expression under MEK inhibitor (MEKi) treatment as a potential predictive biomarker of response to MEKi alone or in combination with PI3K-mTOR pathway inhibitor in pancreatic adenocarcinoma in vitro and ex vivo models (2015) (0)
- Dosage A djustment a nd P harmacokinetic P rofile o f I rinotecan in C ancer P atients W ith H epatic D ysfunction (2002) (0)
- Abstract A228: TGF-beta signaling inhibition using LY2157299 affects proliferation or invasion in hepatocarcinoma cells and patient samples. (2013) (0)
- 402 Dual Inhibition of the MEK and the PI3K-Akt-mTOR Pathways Using GSK1120212 (or UO126) and Everolimus Overcomes Resistance to MEK Inhibitors Used as Single Agents in Pancreatic Cancer Cells (2012) (0)
- Characterization of predictive markers and target genes of ProLindac, a novel DACH-platinum compound, compared to oxaliplatin and cisplatin in human cancer cell lines (2008) (0)
- Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment (2014) (0)
- Compte rendu du 16th breast cancer symposium, San Antonio, 5 novembre 1993 (1994) (0)
- Abstract 4096: Stage-defined, transgenic immunocompetent mouse model (ASV-B) to investigate new drugs for hepatocellular carcinoma (2018) (0)
- Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors (2014) (0)
- Abstract A188: MET inhibition by SU11274 impairs proliferation, motility, and invasion in hepatocellular and cholangiocarcinomas. (2011) (0)
- Patterns and predictive factors of recurrences after complete resection for fibrolamellar hepatocellular carcinoma (2007) (0)
- Abstract 3567: Interaction of pralatrexate with the EGFR/MAPK pathway leads to synergistic activity with EGFR inhibitors (2011) (0)
- Abstract 899: Remarkable anti-tumor response in a HCC transgenic mouse model treated with GNS561 in combination with anti-PD1 (2020) (0)
- Abstract 1911: High MET and CA9 expressions define a subgroup of hepatocellular carcinoma (HCC) patients with poor prognosis candidates for MET inhibition strategy (2015) (0)
- Abstract 2531: Benzofuran derivatives as a novel class of mTOR signaling inhibitors (2014) (0)
- Abstracts of the 6th Annual ENETS Conference, Granada, Spain, March 5–7, 2009 (2009) (0)
- [Irinotecan and liver dysfunctions]. (2007) (0)
- Systemic therapeutic strategies for GEP-NETS: what can we expect in the future? (2013) (0)
- 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup (2022) (0)
- P-139Efficacy of a Sequential Treatment Strategy with GEMOX Followed by FOLFIRI in Advanced Cholangiocarcinoma (2015) (0)
- Impact of surgery and chemotherapy on survival in patients with advanced cholangiocarcinoma: A multivariate analysis in a cohort of 242 consecutive patients. (2006) (0)
- Galunisertib combined with sorafenib affects in vivo tumor growth and immune landscape in hepatocellular carcinoma (HCC) (2016) (0)
- Abstract 3684: Basal Notch1 and Notch4 activation as potential markers of aggressiveness and sensitivity to Notch inhibition in human cancer cell lines (2020) (0)
- Abstract 794: Prognostic value of high c-Met expression in patients with poor prognosis pancreatic adenocarcinoma following surgical resection: comparison of three c-Met scoring methods and exploration of underlying mechanisms of c-Met overexpression (2015) (0)
- Tissue-array analysis of molecular markers of cell signaling and apoptosis in fibrolamellar hepatocellular carcinomas (FL-HCC) (2007) (0)
- Abstract 1080: Link between M1/M2 human macrophages and epithelial-mesenchymal status in head and neck cancer cell lines (2019) (0)
- Abstract 681: PTX-008, a novel galectin-1 targeting agent, improves the effects of cytotoxic drugs in colon cancer cells (2011) (0)
- Evaluation of tumor response to targeted therapies in precision-cut slices of human pancreatic neuroendocrine tumors (2014) (0)
- Abstract 4531: Molecular determinants of sensitivity to pralatrexate in a panel of human cancer cell lines (2011) (0)
- Sunitinib in patients with pancreatic neuroendocrine tumors (panNETs): Exploratory pharmacogenomic analyses. (2019) (0)
- Pharmacokinetics (PK) of irofulven using three different intermittent 5-minutes (MIN) infusion dosing schedules (sch) in advanced solid tumors (AST): Final results (2001) (0)
- Correlation of decreased pS6 expression under MEK inhibitor (MEKi) with response to MEKi alone or combined with PI3K-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models. (2015) (0)
- Rapamycin in patients with advanced hepatocellular carcinoma progressing on prior antiangiogenic therapy. (2012) (0)
- Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products (2013) (0)
- Targeting neuroendocrine tumor: mixing standard options with novel therapies (2012) (0)
- Synergistic effects of ZD9331 a non-polyglutamatable thymidylate synthase inhibitor in combination with SN38 in human colon cancer cells (1999) (0)
- Abstract C20: In vitro effects of Debio 1143, a novel oral IAP inhibitor, in human SCCHN cell lines and tumor specimens. (2013) (0)
- Targeting PPT1 with ezurpimtrostat sensitives liver tumor to immunotherapy by switching cold into hot microenvironments (2023) (0)
- 369 Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib (2012) (0)
- A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. (2015) (0)
- Abstract 1903:In vitroandin vivocharacterization of sunitinib resistance in renal cancer models (2012) (0)
- GNS561 ALONE OR IN COMBINATION WITH CISPLATIN OR GEMCITABINE FOR THE TREATMENT OF INTRAHEPATIC CHOLANGIOCARCINOMA (2019) (0)
- Preliminary results of a phase II study: irinotecan (CPT 11) in chemotherapy naive patients with glioblastoma (1999) (0)
- Abstract A66: Galectin-1 expression correlated with mesenchymal differentiation and resistance to chemotherapy in carcinoma cells (2012) (0)
- Abstract 2836: Downregulation of galectin-1 by OTX-008, a novel calyx[4]arene, is associated with galectin-1 oxidation followed by proteosomal degradation in human head and neck tumor cell lines (2012) (0)
- Population P harmacokinetics o f t he N ovel A nticancer Agent E 7070 D uring F our P hase I S tudies: M odel B uilding and V alidation (2002) (0)
- 534 Ixabepilone, a novel tubulin interacting agent, given every other week in combination with irinotecan in patients with advanced malignancies: a phase i and pharmacokinetic study (2004) (0)
- Cellular effects of MEK inhibition in pancreatic cancer cell lines are not correlated with « classical » predictive markers of response to MEK inhibitors (MEKi) (2013) (0)
- Treatment outcome in patients (pts) with loco-regional relapse (LRR) of undifferentiated carcinoma of nasopharyngeal type (UCNT) (1999) (0)
- Abstract C100: Evaluation of pyriplatin, a monofunctional cationic platinum(II) compound, in human cancer cells (2009) (0)
- Treatment ‰ c nceres (2001) (0)
- Cellular and Molecular Pharmacology of Oxaliplatin 1 (2002) (0)
- Abstract 3484: Ex-vivo cultures of freshly explanted tumor specimens (TIPCAN®), a potent translational approach for screening novel targeted agents (2014) (0)
- Abstract 5124: GNS561 a new quinoline derivative inhibits the growth of hepatocellular carcinoma in a cirrhotic rat and human PDX orthotopic mouse models (2017) (0)
- 563 Ex Vivo Culture of Fresh Tumor Tissues From Patients Assessing Pharmacodynamic (PD) Markers of OTX008, a Novel Galectin-1 Inhibitor: Relevance to Phase I Trial (2012) (0)
- Antiproliferative activity of AP5346, a novel DACH-platinum compound, alone and in combination with other cytotoxics, in human colon and ovarian cancer cells (2007) (0)
- 324 Mechanisms associated with Sunitinib-resistance in human breast carcinomas (2010) (0)
- Ecteinascidin-74 3: A M arine-Derived C ompound i n Advanced, P retreated S arcoma P atients—Prelimi nary Evidence o f A ctivity (2001) (0)
- GNS561, A NEW ORAL CLINICAL-STAGE SMALL MOLECULE COMBINED WITH ANTI-PD1 SHOWED REMARKABLE ANTI-TUMOR EFFECTS IN A TRANSGENIC IMMUNOCOMPETENT HEPATOCELLULAR CARCINOMA MOUSE MODEL (ASV-B) (2019) (0)
- Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies (2022) (0)
- Abstract 4706: Biomarker selection defines a subgroup of hepatocellular carcinoma (HCC) patients with poor prognosis who are candidates for MET inhibition strategy (2014) (0)
- Abstract 4044: LY3039579, a novel Notch inhibit, potentiates the anti-tumoral effects of sorafenib in hepatocellular carcinoma (HCC) (2017) (0)
- Abstract 5103: Bidirectional EMT-dependent modulation of cancer cell and M1/M2 macrophage differentiation (2020) (0)
- Abstract 221: Ex vivo cultures of freshly explanted tumors: a potent translational approach for screening novel targeted agents (2015) (0)
- Abstract B80: Targeting CXCR4/CXCL12 axis as strategy to inhibit tumor cell invasion in RTKi-tolerant HCC models. (2011) (0)
- Abstract A107: c-Met overexpression as an independent prognostic biomarker and therapeutic target in patients with poor prognostic pancreatic adenocarcinoma following surgical resection (2015) (0)
- Posterior Reversible Encephalopathy Occurring During Treatment With Palbociclib (2021) (0)
- Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort (2023) (0)
- Comprar Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract | Eric Raymond | 9782817804293 | Springer (2014) (0)
- Abstract 2178: MET inhibition using SU11274 impairs cellular activities in hepatocellular and Cholangiocarcinomas with high levels of MET and low levels of EGFR expressions. (2013) (0)
- Traitement de cancers (2001) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Eric Raymond?
Eric Raymond is affiliated with the following schools:
